Companion diagnostics has captured the public imagination, and there is no doubt that its role and importance in clinical research, diagnosis, and prescriptions will continue to grow. For professionals seeking business intelligence on this sector, Espicom Ltd. has published a comprehensive guide that informs on business trends, the sometimes murky regulatory framework under which companion diagnostics are governed, and relevant current and potential pharmaceutical products.

The Complete Guide to Companion Diagnostics: Market Environment, Products and Companies provides the following insights, according to the publisher:


• a thorough update on the submission and approval process for companion diagnostics in the United States and Europe
• challenges facing regulators
• market impact
• thirty products that might benefit commercially from having a companion diagnostic
• a review of 27 drugs and their current status in respect to companion diagnostics
• an examination of 26 pharmaceutical companies and their strategic deals with diagnostics companies
• an alanysis of diagnostics companies and their alliances
• approved companion diagnostics and their developers.

The report costs $1740. For more information, go to the Espicom website.

— Norbert Sparrow